Shyam Kumar Gudey

Shyam Kumar Gudey, Ph.D., currently serves as a Principal Scientist at Moderna, having previously held the position of Senior Scientist at Intellia Therapeutics, Inc., where responsibilities included leading assay development and qualification for Immunooncology and ATTR disease pipelines. Shyam has extensive experience in assay development and validation across various companies, including serving as Scientist II at CRISPR Therapeutics, where recognition was received for contributions in Immunooncology. Additional roles include a focus on biomarker assays and cytokine panels at BioAgilytix Boston and involvement in target identification at Sanofi. Shyam's academic credentials include a Ph.D. from Umeå University and advanced studies at Harvard Business School, with a strong background in Medical Sciences and Biotechnology.